Entensive EF Injection

Adult dosage

The dosage and infusion rate are determined based on the patient's fat clearance ability, nitrogen and glucose metabolism capabilities, and nutritional requirements. The dosage should be individualized considering the patient's condition, weight, nutritional and energy requirements, and any additional oral/enteral intake. Children aged 12 years and older and adults: - Normal nutritional status or mild metabolic stress: 0.6-0.9 g/kg of amino acids daily (0.10-0.15 g of nitrogen).

Children's dosage

Children aged 2-11 years: Adjust and administer regularly according to requirement, up to 31 mL/kg daily. Administration rate: Maximum 1.8 mL/kg per hour. Do not exceed 17 hours for administration, recommended to administer over 12-24 hours.

This medication must be used strictly according to a physician's instructions. If fever, chills, skin rash, or difficulty breathing occurs during administration, discontinue use immediately. Caution is required for premature infants or very low-birth-weight babies as the components of this medication might not be properly eliminated from the body, posing a risk. Individuals allergic to fish, eggs, soybeans, peanuts, or those with hypersensitivity to any components of this medication should not use it. Patients with severe liver dysfunction, hyperlipidemia, blood coagulation disorders, or renal failure should also not be administered this medication. Children under 2 years of age should refrain from using this medication for safety. Use with caution in individuals with renal or liver dysfunction or those with diabetes, pancreatitis, or hypothyroidism. Use of this medication may lead to increased heart rate or difficulty breathing, and gastrointestinal symptoms such as nausea, vomiting, and loss of appetite may occur. Additionally, changes in blood pressure, fever, headache, and dizziness might appear, necessitating consultation with a physician if any such symptoms occur. Excessive use can lead to elevated triglyceride levels in the blood, resulting in a serious condition known as fat overload syndrome, hence blood lipid levels must be monitored during administration. This medication can raise blood sugar levels, so diabetic patients must manage their blood sugar rigorously and may require insulin administration. To reduce the risk of infection during administration, maintain a sterile state, particularly when infusing through a central vein, with careful catheter management. Regular blood tests along with monitoring of electrolytes and liver function during prolonged use of this medication are mandatory. The safety of this medication during pregnancy and breastfeeding has not been sufficiently verified. It should only be used when the benefits of treatment outweigh the risks. After administration, components of this medication may affect laboratory test results; hence it is advisable to undergo testing 5-6 hours post-administration. In case of overdose, reduce or discontinue the infusion rate, as there is no specific antidote and symptomatic treatment and careful monitoring are needed. Infusion should not be performed too quickly; it is safer to use an infusion pump for a steady rate of infusion. Do not mix this medication with other drugs, and do not use if the packaging is damaged or if the contents are discolored. Store at a cool place below 25 degrees Celsius and use as soon as possible after mixing. Always consult with a physician when using this medication, and notify them immediately if any adverse symptoms arise.

Serious side effects

• Hives
• severe swelling (edema)
• difficulty breathing
• anaphylactic reaction
• cyanosis
• pallor
• jaundice
• coma.

Mild side effects

Loss of appetite, nausea, vomiting, increased plasma enzyme levels, hypotension, hypertension, slight increase in body temperature, chills, dizziness, headache, skin rash, flushing, feeling hot, feeling cold, pain (in the throat, back, bones, chest, waist), nausea, vomiting, chills, sweating, elevated body temperature, hyperglycemia, increased serum triglyceride levels, serum glucose, electrolytes, osmolality, fluid balance, acid-base status changes, changes in blood cell counts and aggregation reactions, hyperphosphatemia.

This medication should be stored in a sealed container to prevent air ingress, at room temperature between 1 degree and 25 degrees Celsius. This method of storage helps maintain the medication's efficacy and prevents degradation.

Appearance

This medication consists of an inner bag and outer packaging made from plastic material for infusion, divided into three compartments, containing an oxygen absorber in between. Each inner bag compartment contains an amino acid solution and glucose.

Package unit

506 mL/bag [×6 (Component A: 331 mL, Component B: 102 mL, Component C: 73 mL)], 1012 mL/bag [×4 (Component A: 662 mL, Component B: 204 mL, Component C: 146 mL)]